+

WO1999050289A3 - Transformation progression-related genes and their use - Google Patents

Transformation progression-related genes and their use Download PDF

Info

Publication number
WO1999050289A3
WO1999050289A3 PCT/US1999/007187 US9907187W WO9950289A3 WO 1999050289 A3 WO1999050289 A3 WO 1999050289A3 US 9907187 W US9907187 W US 9907187W WO 9950289 A3 WO9950289 A3 WO 9950289A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
progression
related genes
cancer
monitoring
Prior art date
Application number
PCT/US1999/007187
Other languages
French (fr)
Other versions
WO1999050289A2 (en
Inventor
Nan Zhang
Paul B Fisher
Original Assignee
Nan Zhang
Paul B Fisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nan Zhang, Paul B Fisher filed Critical Nan Zhang
Priority to AU34627/99A priority Critical patent/AU3462799A/en
Publication of WO1999050289A2 publication Critical patent/WO1999050289A2/en
Publication of WO1999050289A3 publication Critical patent/WO1999050289A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for cancer diagnosis, monitoring and therapy are disclosed. The compounds provided are progression-related proteins, and portions and variants thereof, as well as polynucleotides that encode such polypeptides, antibodies that bind to such polypeptides and agents that modulate expression of such polypeptides. Vaccines and pharmaceutical compositions comprising such compounds are also provided and may be used, for example, for cancer prevention and treatment. The polypeptides may also be used as markers for monitoring cancer progression in a patient.
PCT/US1999/007187 1998-03-31 1999-03-31 Transformation progression-related genes and their use WO1999050289A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU34627/99A AU3462799A (en) 1998-03-31 1999-03-31 Progression related genes and methods of use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8019398P 1998-03-31 1998-03-31
US60/080,193 1998-03-31

Publications (2)

Publication Number Publication Date
WO1999050289A2 WO1999050289A2 (en) 1999-10-07
WO1999050289A3 true WO1999050289A3 (en) 2000-01-20

Family

ID=22155843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007187 WO1999050289A2 (en) 1998-03-31 1999-03-31 Transformation progression-related genes and their use

Country Status (2)

Country Link
AU (1) AU3462799A (en)
WO (1) WO1999050289A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284362A2 (en) * 1987-03-23 1988-09-28 Imperial Chemical Industries Plc Molecular markers
WO1990002203A1 (en) * 1988-08-19 1990-03-08 Scanlon Kevin J Detection of human tumor progression and drug resistance
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1998042315A1 (en) * 1997-03-21 1998-10-01 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284362A2 (en) * 1987-03-23 1988-09-28 Imperial Chemical Industries Plc Molecular markers
WO1990002203A1 (en) * 1988-08-19 1990-03-08 Scanlon Kevin J Detection of human tumor progression and drug resistance
US5539096A (en) * 1994-09-08 1996-07-23 Universite De Montreal Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines
WO1998042315A1 (en) * 1997-03-21 1998-10-01 The Trustees Of Columbia University In The City Of New York Identification of the progression elevated gene-3 and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONALDO MF ET AL.: "U1-R-E1 Rat c-DNA clone; EST", EMBL SEQUENCE DATABASE, 8 May 1998 (1998-05-08), HEIDELBERG DE, XP002112265 *
SU Z-Z ET AL: "Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 94, no. 17, August 1997 (1997-08-01), NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US, pages 9125 - 9130, XP002112264, ISSN: 0027-8424 *
SYKES D.E. ET AL.: "Rattus norvegicus clone C426 intestinal epithelium proliferating cell-associated mRNA sequences", EMBL SEQUENCE DATABASE, 13 April 1995 (1995-04-13), HEIDELBERG DE, XP002112263 *

Also Published As

Publication number Publication date
AU3462799A (en) 1999-10-18
WO1999050289A2 (en) 1999-10-07

Similar Documents

Publication Publication Date Title
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1997025426A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2000061612A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1999038973A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
HUP0203035A2 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2002074237A8 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
WO1998045328A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000061756A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IL207012A (en) Pharmaceutical composition comprising sgp28 and a vaccine composition for the treatment of a cancer expressing sgp28
BR0111024A (en) Compositions and methods for breast cancer therapy and diagnosis
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000061753A3 (en) Compositions and methods for the treatment and diagnosis of breast cancer
WO1999050289A3 (en) Transformation progression-related genes and their use
WO1999037775A3 (en) Compositions and methods for detecting and treating breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载